Drug intelligence / Profile preview

WR909388

Development stage: Phase 1
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral (studied As Microdose)

Overview

WR909388 is a small molecule triazine compound that has been studied in early-phase clinical research. It was included in an open-label, randomized, fixed-sequence microdose study alongside other triazine compounds (such as WR826647) to assess pharmacokinetics and bioavailability. The primary therapeutic area associated with this class of compounds is infectious diseases, with particular interest in malaria; however, there are no reported indications or associated conditions for WR909388 specifically. No advanced development or efficacy data are available for this compound[1][2][3][4].

Beyond the preview

Go deeper on WR909388.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WR909388.

Explore the full profile